Pharmacogenetic polymorphisms affecting bisoprolol response Castaño Amores, Celia Díaz Villamarín, Xando Pérez Gutiérrez, Ana María Antúnez Rodríguez, Alba Pozo Agundo, Ana Moreno Escobar, Eduardo Sánchez Ramos, Jesús Gabriel Martínez González, Luis Javier Dávila Fajardo, Cristina Lucía Bisoprolol Pharmacogenetic Beta-blockers Cardiovascular diseases Personalized medicine This article is part of the thesis: Analysis of genetic variants associated with response to bisoprolol in patients with acute coronary syndrome with percutaneous coronary intervention with stent, within the doctoral program in Pharmacy at the University of Granada, to whom we thank for their collaboration. We would like to thank Dr. T. Eschenhagen and Dr. K. Kontula for sharing with us detailed information from their articles [16,22] which have allowed us to perform the meta-analysis. β-blockers are commonly prescribed to treat multiple cardiovascular (CV) diseases, but, frequently, adverse drug reactions and intolerance limit their use in clinical practice. Interindividual variability in response to β-blockers may be explained by genetic differences. In fact, pharmacogenetic interactions for some of these drugs have been widely studied, such as metoprolol. But studies that explore genetic variants affecting bisoprolol response are inconclusive, limited or confusing because of mixed results with other β-Blockers, different genetic polymorphisms observed, endpoint studied etc. Because of this, we performed a systematic review in order to find relevant genetic variants affecting bisoprolol response. We have found genetic polymorphism in several genes, but most of the studies focused in ADRB variants. The ADRB1 Arg389Gly (rs1801253) was the most studied genetic polymorphism and it seems to influence the response to bisoprolol, although studies are inconclusive. Even, we performed a meta-analysis about its influence on systolic/diastolic blood pressure in patients treated with bisoprolol, but this did not show statistically significant results. In conclusion, many genetic polymorphisms have been assessed about their influence on patients´ response to bisoprolol and the ADRB1 Arg389Gly (rs1801253) seems the most relevant genetic polymorphism in this regard but results have not been confirmed with a meta-analysis. Our results support the need of further studies about the impact of genetic variants on bisoprolol response, considering different genetic polymorphisms and conducting single and multiple SNPs analysis, including other clinical parameters related to bisoprolol response in a multivariate study. 2021-12-01T08:11:29Z 2021-12-01T08:11:29Z 2021-08-27 journal article Celia Castaño-Amores... [et al.]. Pharmacogenetic polymorphisms affecting bisoprolol response, Biomedicine & Pharmacotherapy, Volume 142, 2021, 112069, ISSN 0753-3322, [https://doi.org/10.1016/j.biopha.2021.112069] http://hdl.handle.net/10481/71836 10.1016/j.biopha.2021.112069 eng http://creativecommons.org/licenses/by-nc-nd/3.0/es/ open access Atribución-NoComercial-SinDerivadas 3.0 España Elsevier